A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Company Overview We are a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Our most advanced molecules are in Phase 3 registrational studies for various cancer indications and we expect our next wave of clinical-stage molecules to come from our inflammation and autoimmune disease programs. Our vision is to leverage our internal small-molecule discovery capabilities to create, develop and commercialize highly differentiated therapies that can have a meaningful impact on patients. The chart below summarizes our current clinical and late pre-clinical stage portfolio: * Taiho holds exclusive licenses in Japan and certain other Asian countries, excluding China, for casdatifan (the “Taiho Territory”). † Gilead and Arcus co-develop globally and share co-promotion rights in the U.S. for domvanalimab and quemliclustat. Gilead holds commercialization rights outside of the U.S.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 247M | 247M | 258M | - | - | 383M |
| Net Income | -353M | -353M | -283M | -307M | -267M | 53M |
| EPS | $-3.29 | $-3.29 | $-3.14 | $-4.15 | $-3.71 | $0.71 |
| Free Cash Flow | -484M | -484M | -176M | -330M | 432M | -282M |
| ROIC | -60.0% | -55.9% | -56.9% | -54.9% | -35.6% | 7.7% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.16 | 0.16 | 0.10 | 0.00 | 1.05 | 0.15 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -386M | -386M | -330M | -340M | -280M | 54M |
| Operating Margin | -156.3% | -156.3% | -127.9% | - | - | 14.1% |
| ROE | -55.9% | -63.3% | -59.8% | -54.9% | -35.6% | 7.9% |
| Shares Outstanding | 107M | 107M | 90M | 74M | 72M | 75M |
Arcus Biosciences, Inc. passes 2 of 9 quality checks, indicating weak fundamentals.
At current prices, the estimated annualized return to fair value is +50.7%.
Arcus Biosciences, Inc. (RCUS) has a 5-year average return on invested capital (ROIC) of -39.1%. This is below average and may indicate limited pricing power.
Arcus Biosciences, Inc. (RCUS) has a market capitalization of $2.5B. It is classified as a mid-cap stock.
Arcus Biosciences, Inc. (RCUS) does not currently pay a regular dividend.
Arcus Biosciences, Inc. (RCUS) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Arcus Biosciences, Inc. (RCUS) reported annual revenue of $247 million in its most recent fiscal year, based on SEC EDGAR filings.
Arcus Biosciences, Inc. (RCUS) has a net profit margin of -142.9%. The company is currently unprofitable.
Arcus Biosciences, Inc. (RCUS) generated $-484 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Arcus Biosciences, Inc. (RCUS) has a debt-to-equity ratio of 0.16. This indicates a conservatively financed balance sheet.
Arcus Biosciences, Inc. (RCUS) reported earnings per share (EPS) of $-3.29 in its most recent fiscal year.
Arcus Biosciences, Inc. (RCUS) has a return on equity (ROE) of -63.3%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 9 years of financial data for Arcus Biosciences, Inc. (RCUS), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Arcus Biosciences, Inc. (RCUS) has a book value per share of $5.88, based on its most recent annual SEC filing.